

INFLIXIMAB

(Including Remicade and biosimilars: Renflexis, Avsola)

Fax to 713-489-9955 Email:Referrals@curbsideinfusion.com

	Email:Referrals@curbsideinfusion.com
PATIENT DEMOGRAPHICS	
Patient Name:	Patient's Phone Number:
Date of Birth:	Address:
Allergies: See List □ NKDA □	City, State, Zip:
Weight:lbs orkg	Patient's Email:
REQUIRED DOCUMENTATION	
Insurance Card	aphics • Medication List • Tried/Failed Therapies • Negative TB Results
LABS: PLEASE INCLUDE FREQUENCY	. ,
Labs patient should be reminded to have drawn	
PRIMARY DIAGNOSIS	
 K50.00 Crohn's disease of small intestine without complication K50.10 Crohn's disease of large intestine without complication K50.90 Crohn's disease, unspecified without complication K51.00 Ulcerative (chronic) pancolitis without complication 	ations
PRE-MEDICATIONS	
 ☑ Per infusion clinic protocol, there are no recommended sta □ Provider Prescribed: 	
PRIMARY MEDICATION ORDER	
Remicade or biosimilar (Renflexis, Avsola) may be used acc To prohibit auto-substitution, please indicate specific brand r	
☐ Infliximab 3 mg/kg (mg) IV at weeks 0, 2, 6, and 6 ☐ Infliximab 5 mg/kg (mg) IV at weeks 0, 2, 6, and 6 ☐ Infliximab 10 mg/kg (mg) IV at weeks 0, 2, 6, and ☐ Infliximabmg/kg (mg) IV every ☐ Other:	every 8 weeks thereafter If every 8 weeks thereafter
· First Dose: Y N	
Refill x12 months unless otherwise noted:	
LINE USE/CARE ORDERS ☑ Start PIV/ACCESS CVC ☑ Flush device per Curbside In ☐ Other Flush Orders: Please fax other line care orders if ch	
ADVERSE REACTION & ANAPHYLAXIS ORDERS	
 ✓ Administer acute infusion reaction and anaphylaxis medica Curbside Infusion Venture protocol 	ations per
PROVIDER INFORMATION: PLEASE CHECK PREFERR	RED FORM OF COMMUNICATION
Provider Name:	Office Contact:
Address:	Phone:
City, State, Zip:	□ Fax:
NPI AND License:	□ Email:
	·
Provider Signature	Date

^{**}The information contained in this document will become a legal prescription. Follow all state Medical Board guidelines when completing, inclusive of guidelines that pertain to the number of prescriptions allowed on a single prescription form. If more than one page is required, make additional copies. Use state board mandated language for dispensing brand name medications or generic substitution and follow physician signature requirements. Confidentiality Statement: This message is intended only for the individual or entity to which it is addressed. It may contain information which may be proprietary and confidential. It may also contain privileged, confidential information which is exempt from disclosure under applicable laws, including the Health Insurance Portability and Accountability Act (HIPAA). If you are not the intended recipient, please note that you are strictly prohibited from disseminating or distributing this information (other than to the intended recipient) or copying this information. If you received this communication in error, please notify the sender immediately at the address and telephone number set forth herein and obtain instructions as to proper destruction of the transmitted material.